Frontline Triplet Menin Inhibitors in Acute Myeloid Leukemia
- Menin inhibitors are emerging as an important tool in AML, but their optimal role is still taking shape, Dr. Tiffany Tanaka, a hematologist/medical oncologist at UC San Diego Health, tells SurvivorNet Connect. While monotherapy offers meaningful responses, resistance limits durability — driving growing interest in combination strategies and earlier use to achieve deeper remissions and improve transplant outcomes, she says.
- As single agents, menin inhibitors produce CR rates in the 20-30% range and overall response rates of ~40-50%, primarily serving elderly or unfit patients in the salvage setting. However, resistance develops frequently, including MEN1 mutations in up to ~40% of patients treated with revumenib.
- The major excitement lies in combining menin inhibitors with azacitidine and venetoclax, or even intensive chemotherapy, to achieve deeper MRD-negative remissions, improved durability, and more reliable bridges to allogeneic transplant.
- As menin inhibitors move beyond salvage monotherapy into combination and frontline strategies, AML clinicians gain greater flexibility in sequencing therapies across disease stages, rather than relying on a single fixed pathway.
The therapeutic landscape of AML has evolved rapidly with the introduction of molecularly targeted therapies. Among the most impactful recent advances is the development of menin inhibitors for NPM1m and KMT2Ar AML, two biologically defined subtypes characterized by dependence on the menin-KMT2A transcriptional complex. By disrupting the interaction between menin and oncogenic transcription, these agents induce leukemic differentiation and suppress self-renewal programs, resulting in clinically meaningful anti-leukemic activity.
Although menin inhibitors were initially developed in the relapsed/refractory (R/R) setting, emerging data now support their incorporation into frontline triplet regimens, with the goal of achieving deeper remissions, higher rates of measurable residual disease (MRD) negativity, and more durable outcomes than those seen with hypomethylating agent based doublets alone.
“This is definitely a really rapidly evolving space in AML right now,” Dr. Tiffany Tanaka, a hematologist/medical oncologist at UC San Diego Health, tells SurvivorNet Connect.
The combination of venetoclax and azacitidine is an established standard of care for older or unfit patients with newly diagnosed AML. However, despite high initial response rates, outcomes remain suboptimal in certain molecular subgroups, including NPM1m AML in elderly patients and KMT2Ar AML, where relapse remains common and remissions are often not durable.
Preclinical studies demonstrate additive and synergistic activity when menin inhibitors are combined with venetoclax and azacitidine with complementary biology.
“The downside to using monotherapy is there’s a fairly high rate of treatment resistance that does develop … so that’s why we’re really looking forward to combination treatment where we can see not only improved outcomes, but better durability and more success to bridging the patient to the curative transplant,” Dr. Tanaka adds.
The Data: Revumenib, Venetoclax & Azacitidine
The most mature data for upfront menin inhibitor‑based triplet therapy come from a phase 1b dose‑escalation and expansion study of azacitidine, venetoclax, and revumenib in newly diagnosed older adults with NPM1m or KMT2Ar AML as part of the BEAT AML Master Trial (NCT03013998).
In the initial cohort of 43 treated patients, the triplet regimen demonstrated substantial clinical activity, with an overall response rate of 88.4%, including responses in approximately 85% of NPM1m patients and 100% of KMT2Ar patients.
- The composite complete remission rate was 81.4%, with a complete remission rate of 67.4%.
- No patients exhibited refractory disease following 1-2 cycles, and responses were rapid, with a median time to first response of 28 days; notably, 84% of responders achieved remission during the first cycle.
- Among 37 evaluable patients, all achieved MRD negativity by centralized flow cytometry.
While these results are promising, it is important to note that they are interim and derived from a single‑arm, early‑phase cohort and the study is ongoing. Median overall survival and event‑free survival data are emerging but remain preliminary. The toxicity profile reflected the known safety signals of the triplet components. Differentiation syndrome and QTc prolongation were observed and generally manageable; the most common non‑hematologic adverse events included nausea, constipation, and vomiting.
Grade ≥3 non‑hematologic events were rare, and no new safety signals emerged compared with the expected profiles of the individual agents.
Updated interim data presented at ASH 2025 and highlighted by Syndax reinforced these findings. In an expanded cohort of 46 efficacy-evaluable patients treated across two dose levels of revumenib, the composite remission rate exceeded 95%, with approximately 95% of responders achieving MRD negativity. Notably, 27% of patients proceeded to allogeneic hematopoietic stem cell transplantation.
Ziftomenib Triplet Combinations
Ziftomenib, currently approved as monotherapy for relapsed or refractory NPM1-mutated AML, has demonstrated clinically meaningful single-agent activity, with an overall response rate of approximately 33% in heavily pretreated patients, a composite complete remission rate of 22%, and a median overall survival of 6.6 months. Differentiation syndrome was reported in approximately one quarter of patients but was largely low grade and manageable, with no reported grade 4 or 5 events.
Early investigational data from the phase I KOMET-007 trial evaluating ziftomenib in combination with venetoclax and azacitidine in relapsed or refractory NPM1-mutated or KMT2A-rearranged AML suggest encouraging activity, with objective response rates of 65% in the NPM1-mutated cohort and 41% in the KMT2A-rearranged cohort.
Composite remission rates were 48% and 28%, respectively, and a substantial proportion of responders achieved MRD negativity. Toxicities observed with the triplet were consistent with the known safety profiles of each agent, including myelosuppression and infrequent differentiation syndrome, and were generally manageable with supportive care. Although these data are derived from relapsed or refractory populations, they provide early proof-of-concept supporting further investigation of ziftomenib-based triplet regimens in the frontline setting.
Clinical Context
Triplet regimens combining a menin inhibitor with venetoclax and azacitidine represent a biologically compelling and highly active therapeutic strategy for patients with newly diagnosed AML harboring NPM1m or KMT2Ar. Early-phase studies demonstrate high response rates and deep molecular remissions, particularly with revumenib-based combinations.
These findings must be interpreted with caution as they are derived primarily from single-arm, early-phase studies with limited patient numbers, short follow-up, and highly selected populations treated at experienced academic centers. Long-term outcomes, including relapse-free survival and overall survival, remain immature, and the comparative benefit over standard venetoclax-based therapy has not yet been established.
In addition, the safety and logistical complexity of triplet therapy including differentiation syndrome, QTc monitoring, and prolonged cytopenias may limit generalizability outside specialized centers.
Menin inhibitor based triplet regimens should currently be considered investigational and used only within the context of well-designed clinical trials. Ongoing and planned randomized studies will be essential to define their true clinical benefit, optimal patient selection, and role in the frontline management of molecularly defined AML.
